Clinical proteomics-driven precision medicine for targeted cancer therapy: current overview and future perspectives

References

• Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.
   PubMed Web of Science ®Google Scholar
• Marusyk A, Almendro V, Polyak K. Intra-tumour heterogeneity: a looking glass for cancer?. Nat Rev Cancer. 2012;12(5):323–334.
   PubMed Web of Science ®Google Scholar
• Petricoin EF, Zoon KC, Kohn EC, et al. Clinical proteomics: translating benchside promise into bedside reality. Nat Rev Drug Discov. 2002;1(9):683–695.
   PubMed Web of Science ®Google Scholar
• Apweiler R, Aslanidis C, Deufel T, et al. Approaching clinical proteomics: current state and future fields of application in fluid proteomics. Clin Chem Lab Med CCLM/FESCC. 2009;47(6):724–744.
   PubMed Web of Science ®Google Scholar
• Mischak H, Apweiler R, Banks RE, et al. Clinical proteomics: a need to define the field and to begin to set adequate standards. PROTEOMICS-Clin Appl. 2007;1(2):148–156.
   PubMed Web of Science ®Google Scholar
• Mendelsohn J. Personalizing oncology: perspectives and prospects. J Clin Oncol Off J Am Soc Clin Oncol. 2013;31(15):1904–1911.
   PubMed Web of Science ®Google Scholar
• Jameson JL, Longo DL. Precision medicine–personalized, problematic, and promising. N Engl J Med. 2015;372(23):2229–2234.
   PubMed Web of Science ®Google Scholar
• National Research Council. Toward precision medicine: building a knowledge network for biomedical research and a new taxonomy of disease [ Internet]. Washington, DC: National Academies Press; 2011. Available from: (http://www.nap.edu/catalog/13284/toward-precision-medicine-building-a-knowledge-network-for-biomedical-research).)
   Google Scholar
• Collins FS, Varmus H. A new initiative on precision medicine. N Engl J Med. 2015;372(9):793–795.
   PubMed Web of Science ®Google Scholar
• Shrager J, Tenenbaum JM. Rapid learning for precision oncology. Nat Rev Clin Oncol. 2014;11(2):109–118.
   PubMed Web of Science ®Google Scholar
• Blau CA, Liakopoulou E. Can we deconstruct cancer, one patient at a time?. Trends Genet TIG. 2013;29(1):6–10.
   PubMed Web of Science ®Google Scholar
• Wisniewski JR, Dus K, Mann M. Proteomic workflow for analysis of archival formalin-fixed and paraffin-embedded clinical samples to a depth of 10 000 proteins. Proteomics Clin Appl. 2013;7(3–4):225–233.
   PubMed Web of Science ®Google Scholar
• Bauer JA, Chakravarthy AB, Rosenbluth JM, et al. Identification of markers of taxane sensitivity using proteomic and genomic analyses of breast tumors from patients receiving neoadjuvant paclitaxel and radiation. Clin Cancer Res. 2010;16(2):681–690.
   PubMed Web of Science ®Google Scholar
• Meding S, Balluff B, Elsner M, et al. Tissue-based proteomics reveals FXYD3, S100A11 and GSTM3 as novel markers for regional lymph node metastasis in colon cancer. J Pathol. 2012;228(4):459–470.
   PubMed Web of Science ®Google Scholar
• Wang W, Jia HL, Huang JM, et al. Identification of biomarkers for lymph node metastasis in early-stage cervical cancer by tissue-based proteomics. Br J Cancer. 2014;110(7):1748–1758.
   PubMed Web of Science ®Google Scholar
• Gamez-Pozo A, Sanchez-Navarro I, Nistal M, et al. MALDI profiling of human lung cancer subtypes. PLoS One. 2009;4(11):e7731.
   PubMed Web of Science ®Google Scholar
• Kikuta K, Tochigi N, Saito S, et al. Peroxiredoxin 2 as a chemotherapy responsiveness biomarker candidate in osteosarcoma revealed by proteomics. Proteomics Clin Appl. 2010;4(5):560–567.
   PubMed Web of Science ®Google Scholar
• Tweedle EM, Khattak I, Ang CW, et al. Low molecular weight heat shock protein HSP27 is a prognostic indicator in rectal cancer but not colon cancer. Gut. 2010;59(11):1501–1510.
   PubMed Web of Science ®Google Scholar
• Wang LN, Tong SW, Hu HD, et al. Quantitative proteome analysis of ovarian cancer tissues using a iTRAQ approach. J Cell Biochem. 2012;113(12):3762–3772.
   PubMed Web of Science ®Google Scholar
• Heo SH, Lee SJ, Ryoo HM, et al. Identification of putative serum glycoprotein biomarkers for human lung adenocarcinoma by multilectin affinity chromatography and LC–MS/MS. Proteomics. 2007;7(23):4292–4302.
   PubMed Web of Science ®Google Scholar
• Zeng X, Hood BL, Sun M, et al. Lung cancer serum biomarker discovery using glycoprotein capture and liquid chromatography mass spectrometry. J Proteome Res. 2010;9(12):6440–6449.
   PubMed Web of Science ®Google Scholar
• Kang SM, Sung HJ, Ahn JM, et al. The Haptoglobin beta chain as a supportive biomarker for human lung cancers. Mol Biosyst. 2011;7(4):1167–1175.
   PubMed Web of Science ®Google Scholar
• Pitteri SJ, Amon LM, Busald Buson T, et al. Detection of elevated plasma levels of epidermal growth factor receptor before breast cancer diagnosis among hormone therapy users. Cancer Res. 2010;70(21):8598–8606.
   PubMed Web of Science ®Google Scholar
• Murakoshi Y, Honda K, Sasazuki S, et al. Plasma biomarker discovery and validation for colorectal cancer by quantitative shotgun mass spectrometry and protein microarray. Cancer Sci. 2011;102(3):630–638.
   PubMed Web of Science ®Google Scholar
• Chen YT, Chen CL, Chen HW, et al. Discovery of novel bladder cancer biomarkers by comparative urine proteomics using iTRAQ technology. J Proteome Res. 2010;9(11):5803–5815.
   PubMed Web of Science ®Google Scholar
• True LD, Zhang H, Ye M, et al. CD90/THY1 is overexpressed in prostate cancer-associated fibroblasts and could serve as a cancer biomarker. Modern Pathol. 2010;23(10):1346–1356.
   PubMed Web of Science ®Google Scholar
• Ang CS, Rothacker J, Patsiouras H, et al. Use of multiple reaction monitoring for multiplex analysis of colorectal cancer-associated proteins in human feces. Electrophoresis. 2011;32(15):1926–1938.
   PubMed Web of Science ®Google Scholar
• Ang CS, Nice EC. Targeted in-gel MRM: a hypothesis driven approach for colorectal cancer biomarker discovery in human feces. J Proteome Res. 2010;9(9):4346–4355.
   PubMed Web of Science ®Google Scholar
• Xiao H, Zhang L, Zhou H, et al. Proteomic analysis of human saliva from lung cancer patients using two-dimensional difference gel electrophoresis and mass spectrometry. Mol Cell Proteom MCP. 2012;11(2):M111 012112.
   PubMed Web of Science ®Google Scholar
• Zabron AA, Horneffer-Van Der Sluis VM, Wadsworth CA, et al. Elevated levels of neutrophil gelatinase-associated lipocalin in bile from patients with malignant pancreatobiliary disease. Am J Gastroenterol. 2011;106(9):1711–1717.
   PubMed Web of Science ®Google Scholar
• Desiderio C, D’Angelo L, Rossetti DV, et al. Cerebrospinal fluid top-down proteomics evidenced the potential biomarker role of LVV- and VV-hemorphin-7 in posterior cranial fossa pediatric brain tumors. Proteomics. 2012;12(13):2158–2166.
   PubMed Web of Science ®Google Scholar
• Kosanam H, Makawita S, Judd B, et al. Mining the malignant ascites proteome for pancreatic cancer biomarkers. Proteomics. 2011;11(23):4551–4558.
   PubMed Web of Science ®Google Scholar
• Haslene-Hox H, Oveland E, Woie K, et al. Increased WD-repeat containing protein 1 in interstitial fluid from ovarian carcinomas shown by comparative proteomic analysis of malignant and healthy gynecological tissue. Biochim Biophys Acta. 2013;1834(11):2347–2359.
   PubMed Web of Science ®Google Scholar
• Dogan A. Advances in clinical applications of tissue proteomics: opportunities and challenges. Expert Rev Proteomics. 2014;11(5):531–533.
   PubMed Web of Science ®Google Scholar
• Casadonte R, Caprioli RM. Proteomic analysis of formalin-fixed paraffin-embedded tissue by MALDI imaging mass spectrometry. Nat Protoc. 2011;6(11):1695–1709.
   PubMed Web of Science ®Google Scholar
• Fowler CB, O’Leary TJ, Mason JT. Toward improving the proteomic analysis of formalin-fixed, paraffin-embedded tissue. Expert Rev Proteomics. 2013;10(4):389–400.
   PubMed Web of Science ®Google Scholar
• Angel PM, Caprioli RM. Matrix-assisted laser desorption ionization imaging mass spectrometry: in situ molecular mapping. Biochemistry. 2013;52(22):3818–3828.
   PubMed Web of Science ®Google Scholar
• Balluff B, Elsner M, Kowarsch A, et al. Classification of HER2/neu status in gastric cancer using a breast-cancer derived proteome classifier. J Proteome Res. 2010;9(12):6317–6322.
   PubMed Web of Science ®Google Scholar
• Lindskog C. The potential clinical impact of the tissue-based map of the human proteome. Expert Rev Proteomics. 2015;12(3):213–215.
   PubMed Web of Science ®Google Scholar
• Xu BJ. Combining laser capture microdissection and proteomics: methodologies and clinical applications. Proteomics Clin Appl. 2010;4(2):116–123.
   PubMed Web of Science ®Google Scholar
• Imielinski M, Cha S, Rejtar T, et al. Integrated proteomic, transcriptomic, and biological network analysis of breast carcinoma reveals molecular features of tumorigenesis and clinical relapse. Mol Cell Proteom MCP. 2012;11(6):M111 014910.
   PubMed Web of Science ®Google Scholar
• Datta S, Malhotra L, Dickerson R, et al. Laser capture microdissection: Big data from small samples. Histol Histopathol. 2015;30(11):1255–1269.
   PubMed Web of Science ®Google Scholar
• Indovina P, Marcelli E, Pentimalli F, et al. Mass spectrometry-based proteomics: The road to lung cancer biomarker discovery. Mass Spectrom Rev. 2013;32(2):129–142.
   PubMed Web of Science ®Google Scholar
• Hanash SM, Baik CS, Kallioniemi O. Emerging molecular biomarkers–blood-based strategies to detect and monitor cancer. Nat Rev Clin Oncol. 2011;8(3):142–150.
   PubMed Web of Science ®Google Scholar
• Omenn GS, States DJ, Adamski M, et al. Overview of the HUPO Plasma Proteome Project: results from the pilot phase with 35 collaborating laboratories and multiple analytical groups, generating a core dataset of 3020 proteins and a publicly-available database. Proteomics. 2005;5(13):3226–3245.
   PubMed Web of Science ®Google Scholar
• Villanueva J, Shaffer DR, Philip J, et al. Differential exoprotease activities confer tumor-specific serum peptidome patterns. J Clin Invest. 2006;116(1):271–284.
   PubMed Web of Science ®Google Scholar
• Liotta LA, Petricoin EF. Mass spectrometry-based protein biomarker discovery: solving the remaining challenges to reach the promise of clinical benefit. Clin Chem. 2010;56(10):1641–1642.
   PubMed Web of Science ®Google Scholar
• Gold L, Walker JJ, Wilcox SK, et al. Advances in human proteomics at high scale with the SOMAscan proteomics platform. N Biotechnol. 2012;29(5):543–549.
   PubMed Web of Science ®Google Scholar
• Taguchi A, Hanash SM. Unleashing the power of proteomics to develop blood-based cancer markers. Clin Chem. 2013;59(1):119–126.
   PubMed Web of Science ®Google Scholar
• Gewinner C, Hart G, Zachara N, et al. The coactivator of transcription CREB-binding protein interacts preferentially with the glycosylated form of Stat5. J Biol Chem. 2004;279(5):3563–3572.
   PubMed Web of Science ®Google Scholar
• Dube DH, Bertozzi CR. Glycans in cancer and inflammation–potential for therapeutics and diagnostics. Nat Rev Drug Discov. 2005;4(6):477–488.
   PubMed Web of Science ®Google Scholar
• Kyselova Z, Mechref Y, Kang P, et al. Breast cancer diagnosis and prognosis through quantitative measurements of serum glycan profiles. Clin Chem. 2008;54(7):1166–1175.
   PubMed Web of Science ®Google Scholar
• Narayanasamy A, Ahn JM, Sung HJ, et al. Fucosylated glycoproteomic approach to identify a complement component 9 associated with squamous cell lung cancer (SQLC). J Proteomics. 2011;74(12):2948–2958.
   PubMed Web of Science ®Google Scholar
• Tsai HY, Boonyapranai K, Sriyam S, et al. Glycoproteomics analysis to identify a glycoform on haptoglobin associated with lung cancer. Proteomics. 2011;11(11):2162–2170.
   PubMed Web of Science ®Google Scholar
• Pang WW, Abdul-Rahman PS, Wan-Ibrahim WI, et al. Can the acute-phase reactant proteins be used as cancer biomarkers?. Int J Biol Markers. 2010;25(1):1–11.
   PubMed Web of Science ®Google Scholar
• Sung HJ, Ahn JM, Yoon YH, et al. Identification and validation of SAA as a potential lung cancer biomarker and its involvement in metastatic pathogenesis of lung cancer. J Proteome Res. 2011;10(3):1383–1395.
   PubMed Web of Science ®Google Scholar
• Sanchez-Carbayo M. Antibody array-based technologies for cancer protein profiling and functional proteomic analyses using serum and tissue specimens. Tumour Biol J Int Soc Oncodevelopmental Biol Med. 2010;31(2):103–112.
   PubMed Web of Science ®Google Scholar
• Reumer A, Maes E, Mertens I, et al. Colorectal cancer biomarker discovery and validation using LC–MS/MS-based proteomics in blood: truth or dare?. Expert Rev Proteomics. 2014;11(4):449–463.
   PubMed Web of Science ®Google Scholar
• Ray S, Reddy PJ, Jain R, et al. Proteomic technologies for the identification of disease biomarkers in serum: advances and challenges ahead. Proteomics. 2011;11(11):2139–2161.
   PubMed Web of Science ®Google Scholar
• Tan HT, Lee YH, Chung MC. Cancer proteomics. Mass Spectrom Rev. 2012;31(5):583–605.
   PubMed Web of Science ®Google Scholar
• Rai AJ, Gelfand CA, Haywood BC, et al. HUPO Plasma Proteome Project specimen collection and handling: towards the standardization of parameters for plasma proteome samples. Proteomics. 2005;5(13):3262–3277.
   PubMed Web of Science ®Google Scholar
• Omenn GS. Advancement of biomarker discovery and validation through the HUPO plasma proteome project. Dis Markers. 2004;20(3):131–134.
   PubMed Web of Science ®Google Scholar
• Ray S, Mehta G, Srivastava S. Label-free detection techniques for protein microarrays: prospects, merits and challenges. Proteomics. 2010;10(4):731–748.
   PubMed Web of Science ®Google Scholar
• Ladd J, Taylor AD, Piliarik M, et al. Label-free detection of cancer biomarker candidates using surface plasmon resonance imaging. Anal Bioanal Chem. 2009;393(4):1157–1163.
   PubMed Web of Science ®Google Scholar
• Lee SJ, Youn BS, Park JW, et al. ssDNA aptamer-based surface plasmon resonance biosensor for the detection of retinol binding protein 4 for the early diagnosis of type 2 diabetes. Anal Chem. 2008;80(8):2867–2873.
   PubMed Web of Science ®Google Scholar
• Lausted C, Hu Z, Hood L. Quantitative serum proteomics from surface plasmon resonance imaging. Mol Cell Proteom MCP. 2008;7(12):2646–2474.
   Web of Science ®Google Scholar
• Okuno J, Maehashi K, Kerman K, et al. Label-free immunosensor for prostate-specific antigen based on single-walled carbon nanotube array-modified microelectrodes. Biosens Bioelectron. 2007;22(9–10):2377–2381.
   PubMed Web of Science ®Google Scholar
• Zheng G, Patolsky F, Cui Y, et al. Multiplexed electrical detection of cancer markers with nanowire sensor arrays. Nat Biotechnol. 2005;23(10):1294–1301.
   PubMed Web of Science ®Google Scholar
• Srivastava S, LaBaer J. Nanotubes light up protein arrays. Nat Biotechnol. 2008;26(11):1244–1246.
   PubMed Web of Science ®Google Scholar
• Zhu H, Dale PS, Caldwell CW, et al. Rapid and label-free detection of breast cancer biomarker CA15-3 in clinical human serum samples with optofluidic ring resonator sensors. Anal Chem. 2009;81(24):9858–9865.
   PubMed Web of Science ®Google Scholar
• Washburn AL, Gunn LC, Bailey RC. Label-free quantitation of a cancer biomarker in complex media using silicon photonic microring resonators. Anal Chem. 2009;81(22):9499–9506.
   PubMed Web of Science ®Google Scholar
• Von Muhlen MG, Brault ND, Knudsen SM, et al. Label-free biomarker sensing in undiluted serum with suspended microchannel resonators. Anal Chem. 2010;82(5):1905–1910.
   PubMed Web of Science ®Google Scholar
• Ang CS, Rothacker J, Patsiouras H, et al. Murine fecal proteomics: a model system for the detection of potential biomarkers for colorectal cancer. J Chromatogr A. 2010;1217(19):3330–3340.
   PubMed Web of Science ®Google Scholar
• Hu S, Loo JA, Wong DT. Human saliva proteome analysis and disease biomarker discovery. Expert Rev Proteomics. 2007;4(4):531–538.
   PubMed Web of Science ®Google Scholar
• Mannello F, Ligi D. Resolving breast cancer heterogeneity by searching reliable protein cancer biomarkers in the breast fluid secretome. BMC Cancer. 2013;13:344.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Pineiro AM, Blanco-Prieto S, Sanchez-Otero N, et al. On the identification of biomarkers for non-small cell lung cancer in serum and pleural effusion. J Proteomics. 2010;73(8):1511–1522.
   PubMed Web of Science ®Google Scholar
• Nilsson T, Mann M, Aebersold R, et al. Mass spectrometry in high-throughput proteomics: ready for the big time. Nat Methods. 2010;7(9):681–685.
   PubMed Web of Science ®Google Scholar
• Wu FX, Ressom H, Dunn MJ. Focus on bioinformatics in proteomics. Proteomics. 2013;13(2):219–220.
   PubMed Web of Science ®Google Scholar
• Grebe SK, Singh RJ. LC–MS/MS in the Clinical Laboratory - Where to From Here?. Clin Biochem Rev Aust Assoc Clin Biochemists. 2011;32(1):5–31.
   PubMedGoogle Scholar
• Chen G, Pramanik BN. Application of LC/MS to proteomics studies: current status and future prospects. Drug Discov Today. 2009;14(9–10):465–471.
   PubMed Web of Science ®Google Scholar
• Picotti P, Bodenmiller B, Mueller LN, et al. Full dynamic range proteome analysis of S. cerevisiae by targeted proteomics. Cell. 2009;138(4):795–806.
   PubMed Web of Science ®Google Scholar
• Hoofnagle AN, Becker JO, Oda MN, et al. Multiple-reaction monitoring-mass spectrometric assays can accurately measure the relative protein abundance in complex mixtures. Clin Chem. 2012;58(4):777–781.
   PubMed Web of Science ®Google Scholar
• Gillette MA, Carr SA. Quantitative analysis of peptides and proteins in biomedicine by targeted mass spectrometry. Nat Methods. 2013;10(1):28–34.
   PubMed Web of Science ®Google Scholar
• Huttenhain R, Soste M, Selevsek N, et al. Reproducible quantification of cancer-associated proteins in body fluids using targeted proteomics. Sci Transl Med. 2012;4(142):142ra194.
   Web of Science ®Google Scholar
• Whiteaker JR, Lin C, Kennedy J, et al. A targeted proteomics-based pipeline for verification of biomarkers in plasma. Nat Biotechnol. 2011;29(7):625–634.
   PubMed Web of Science ®Google Scholar
• Pan S, Chen R, Brand RE, et al. Multiplex targeted proteomic assay for biomarker detection in plasma: a pancreatic cancer biomarker case study. J Proteome Res. 2012;11(3):1937–1948.
   PubMed Web of Science ®Google Scholar
• Percy AJ, Chambers AG, Yang J, et al. Multiplexed MRM-based quantitation of candidate cancer biomarker proteins in undepleted and non-enriched human plasma. Proteomics. 2013;13(14):2202–2215.
   PubMed Web of Science ®Google Scholar
• Kitteringham NR, Jenkins RE, Lane CS, et al. Multiple reaction monitoring for quantitative biomarker analysis in proteomics and metabolomics. J Chromatogr B Analyt Technol Biomed Life Sci. 2009;877(13):1229–1239.
   PubMed Web of Science ®Google Scholar
• Selevsek N, Matondo M, Sanchez Carbayo M, et al. Systematic quantification of peptides/proteins in urine using selected reaction monitoring. Proteomics. 2011;11(6):1135–1147.
   PubMed Web of Science ®Google Scholar
• Keshishian H, Addona T, Burgess M, et al. Quantitative, multiplexed assays for low abundance proteins in plasma by targeted mass spectrometry and stable isotope dilution. Mol Cell Proteom MCP. 2007;6(12):2212–2229.
   PubMed Web of Science ®Google Scholar
• Addona TA, Abbatiello SE, Schilling B, et al. Multi-site assessment of the precision and reproducibility of multiple reaction monitoring-based measurements of proteins in plasma. Nat Biotechnol. 2009;27(7):633–641.
   PubMed Web of Science ®Google Scholar
• Picotti P, Aebersold R. Selected reaction monitoring-based proteomics: workflows, potential, pitfalls and future directions. Nat Methods. 2012;9(6):555–566.
   PubMed Web of Science ®Google Scholar
• Fortin T, Salvador A, Charrier JP, et al. Clinical quantitation of prostate-specific antigen biomarker in the low nanogram/milliliter range by conventional bore liquid chromatography-tandem mass spectrometry (multiple reaction monitoring) coupling and correlation with ELISA tests. Mol Cell Proteom MCP. 2009;8(5):1006–1015.
   PubMed Web of Science ®Google Scholar
• Peng J, Elias JE, Thoreen CC, et al. Evaluation of multidimensional chromatography coupled with tandem mass spectrometry (LC/LC–MS/MS) for large-scale protein analysis: the yeast proteome. J Proteome Res. 2003;2(1):43–50.
   PubMed Web of Science ®Google Scholar
• Dams R, Huestis MA, Lambert WE, et al. Matrix effect in bio-analysis of illicit drugs with LC–MS/MS: influence of ionization type, sample preparation, and biofluid. J Am Soc Mass Spectrom. 2003;14(11):1290–1294.
   PubMed Web of Science ®Google Scholar
• Gros M, Petrović M, Barceló D. Development of a multi-residue analytical methodology based on liquid chromatography–tandem mass spectrometry (LC–MS/MS) for screening and trace level determination of pharmaceuticals in surface and wastewaters. Talanta. 2006;70(4):678–690.
   PubMed Web of Science ®Google Scholar
• Bogdanov B, Smith RD. Proteomics by FTICR mass spectrometry: top down and bottom up. Mass Spectrom Rev. 2005;24(2):168–200.
   PubMed Web of Science ®Google Scholar
• Zhou L, Li Q, Wang J, et al. Oncoproteomics: Trials and Tribulations. Proteomics Clin Appl. 2015.
   Google Scholar
• Yates JR, Ruse CI, Nakorchevsky A. Proteomics by mass spectrometry: approaches, advances, and applications. Annu Rev Biomed Eng. 2009;11:49–79.
   PubMed Web of Science ®Google Scholar
• Cramer R, Gobom J, Nordhoff E. High-throughput proteomics using matrix-assisted laser desorption/ionization mass spectrometry. Expert Rev Proteomics. 2005;2(3):407–420.
   PubMed Web of Science ®Google Scholar
• Rodrigo MAM, Zitka O, Krizkova S, et al. MALDI-TOF MS as evolving cancer diagnostic tool: a review. J Pharm Biomed Anal. 2014;95:245–255.
   PubMed Web of Science ®Google Scholar
• Cho YT, Su H, Wu WJ, et al, Biomarker Characterization by MALDI-TOF/MS. Adv Clin Chem. 2015;69:209–254.
   PubMed Web of Science ®Google Scholar
• Pusch W, Kostrzewa M. Application of MALDI-TOF mass spectrometry in screening and diagnostic research. Curr Pharm Des. 2005;11(20):2577–2591.
   PubMed Web of Science ®Google Scholar
• Castellino S, Groseclose MR, Wagner D. MALDI imaging mass spectrometry: bridging biology and chemistry in drug development. Bioanalysis. 2011;3(21):2427–2441.
   PubMed Web of Science ®Google Scholar
• Cho Y-T, Su H, Huang T-L, et al Matrix-assisted laser desorption ionization/time-of-flight mass spectrometry for clinical diagnosis. Clin Chim Acta. 2013;415:266–275.
   PubMed Web of Science ®Google Scholar
• Iwadate Y. Clinical proteomics in cancer research-promises and limitations of current two-dimensional gel electrophoresis. Curr Med Chem. 2008;15(23):2393–2400.
   PubMed Web of Science ®Google Scholar
• Roman E, Lunde MLS, Miron T, et al. Analysis of protein expression profile of oral squamous cell carcinoma by MALDI-TOF-MS. Anticancer Res. 2013;33(3):837–845.
   PubMed Web of Science ®Google Scholar
• Spengler B. Mass spectrometry imaging of biomolecular information. Anal Chem. 2015;87(1):64–82.
   PubMed Web of Science ®Google Scholar
• Gromov P, Moreira JMA, Gromova I. Proteomic analysis of tissue samples in translational breast cancer research. Expert Rev Proteomics. 2014;11(3):285–302.
   PubMed Web of Science ®Google Scholar
• Rauser S, Deininger S-O, Suckau D, et al. Approaching MALDI molecular imaging for clinical proteomic research: current state and fields of application. Expert Rev Proteomics. 2010;7(6):927–941.
   PubMed Web of Science ®Google Scholar
• Cazares LH, Troyer DA, Wang B, et al. MALDI tissue imaging: from biomarker discovery to clinical applications. Anal Bioanal Chem. 2011;401(1):17–27.
   PubMed Web of Science ®Google Scholar
• Schwamborn K. Imaging mass spectrometry in biomarker discovery and validation. J Proteomics. 2012;75(16):4990–4998.
   PubMed Web of Science ®Google Scholar
• Schwamborn K, Caprioli RM. Molecular imaging by mass spectrometry—looking beyond classical histology. Nat Rev Cancer. 2010;10(9):639–646.
   PubMed Web of Science ®Google Scholar
• Meding S, Nitsche U, Balluff B, et al. Tumor classification of six common cancer types based on proteomic profiling by MALDI imaging. J Proteome Res. 2012;11(3):1996–2003.
   PubMed Web of Science ®Google Scholar
• Schöne C, Höfler H, Walch A. MALDI imaging mass spectrometry in cancer research: combining proteomic profiling and histological evaluation. Clin Biochem. 2013;46(6):539–545.
   PubMed Web of Science ®Google Scholar
• Balluff B, Schöne C, Höfler H, et al. MALDI imaging mass spectrometry for direct tissue analysis: technological advancements and recent applications. Histochem Cell Biol. 2011;136(3):227–244.
   PubMed Web of Science ®Google Scholar
• Minerva L, Clerens S, Baggerman G, et al. Direct profiling and identification of peptide expression differences in the pancreas of control and ob/ob mice by imaging mass spectrometry. Proteomics. 2008;8(18):3763–3774.
   PubMed Web of Science ®Google Scholar
• Gygi SP, Rist B, Gerber SA, et al. Quantitative analysis of complex protein mixtures using isotope-coded affinity tags. Nat Biotechnol. 1999;17(10):994–999.
   PubMed Web of Science ®Google Scholar
• Ross PL, Huang YN, Marchese JN, et al. Multiplexed protein quantitation in Saccharomyces cerevisiae using amine-reactive isobaric tagging reagents. Mol Cell Proteom MCP. 2004;3(12):1154–1169.
   PubMed Web of Science ®Google Scholar
• Geiger T, Wisniewski JR, Cox J, et al. Use of stable isotope labeling by amino acids in cell culture as a spike-in standard in quantitative proteomics. Nat Protoc. 2011;6(2):147–157.
   PubMed Web of Science ®Google Scholar
• DeSouza L, Diehl G, Rodrigues MJ, et al. Search for cancer markers from endometrial tissues using differentially labeled tags iTRAQ and cICAT with multidimensional liquid chromatography and tandem mass spectrometry. J Proteome Res. 2005;4(2):377–386.
   PubMed Web of Science ®Google Scholar
• Burkhart JM, Vaudel M, Zahedi RP, et al. iTRAQ protein quantification: A quality‐controlled workflow. Proteomics. 2011;11(6):1125–1134.
   PubMed Web of Science ®Google Scholar
• Pierce A, Unwin RD, Evans CA, et al. Eight-channel iTRAQ enables comparison of the activity of six leukemogenic tyrosine kinases. Mol Cell Proteomics. 2008;7(5):853–863.
   PubMed Web of Science ®Google Scholar
• Zieske LR. A perspective on the use of iTRAQ™ reagent technology for protein complex and profiling studies. J Exp Bot. 2006;57(7):1501–1508.
   PubMed Web of Science ®Google Scholar
• Mann M. Functional and quantitative proteomics using SILAC. Nat Rev Mol Cell Biol. 2006;7(12):952–958.
   PubMed Web of Science ®Google Scholar
• Ong S-E, Mann M. Mass spectrometry–based proteomics turns quantitative. Nat Chem Biol. 2005;1(5):252–262.
   PubMed Web of Science ®Google Scholar
• Marimuthu A, Subbannayya Y, Sahasrabuddhe NA, et al. SILAC‐based quantitative proteomic analysis of gastric cancer secretome. PROTEOMICS-Clin Appl. 2013;7(5–6):355–366.
   PubMed Web of Science ®Google Scholar
• Bantscheff M, Lemeer S, Savitski MM, et al. Quantitative mass spectrometry in proteomics: critical review update from 2007 to the present. Anal Bioanal Chem. 2012;404(4):939–965.
   PubMed Web of Science ®Google Scholar
• Xie F, Liu T, Qian W-J, et al. Liquid chromatography-mass spectrometry-based quantitative proteomics. J Biol Chem. 2011;286(29):25443–25449.
   PubMed Web of Science ®Google Scholar
• Levin Y, Schwarz E, Wang L, et al. Label-free LC–MS/MS quantitative proteomics for large-scale biomarker discovery in complex samples. J Sep Sci. 2007;30(14):2198–2203.
   PubMed Web of Science ®Google Scholar
• Acosta-Martin AE, Lane L. Combining bioinformatics and MS-based proteomics: clinical implications. Expert Rev Proteomics. 2014;11(3):269–284.
   PubMed Web of Science ®Google Scholar
• Neilson KA, Ali NA, Muralidharan S, et al. Less label, more free: approaches in label-free quantitative mass spectrometry. Proteomics. 2011;11(4):535–553.
   PubMed Web of Science ®Google Scholar
• Zhang B, VerBerkmoes NC, Langston MA, et al. Detecting differential and correlated protein expression in label-free shotgun proteomics. J Proteome Res. 2006;5(11):2909–2918.
   PubMed Web of Science ®Google Scholar
• Pham TV, Piersma SR, Oudgenoeg G, et al. Label-free mass spectrometry-based proteomics for biomarker discovery and validation. Expert Rev Mol Diagn. 2012;12(4):343–359.
   PubMed Web of Science ®Google Scholar
• Orchard S. Data standardization and sharing—the work of the HUPO-PSI. Biochim Biophys Acta (BBA)-Proteins Proteom. 2014;1844(1):82–87.
   Web of Science ®Google Scholar
• Turewicz M, Deutsch EW Spectra, chromatograms, metadata: mzML-the standard data format for mass spectrometer output. In: Data mining in proteomics. Springer; 2011. p. 179–203.
   Google Scholar
• Walzer M, Qi D, Mayer G, et al. The mzQuantML data standard for mass spectrometry–based quantitative studies in proteomics. Mol Cell Proteomics. 2013;12(8):2332–2340.
   PubMed Web of Science ®Google Scholar
• Field HI, Fenyo D, Beavis RC. RADARS, a bioinformatics solution that automates proteome mass spectral analysis, optimises protein identification, and archives data in a relational database. Proteomics. 2002;2(1):36.
   PubMed Web of Science ®Google Scholar
• Srinivas PR, Verma M, Zhao Y, et al. Proteomics for cancer biomarker discovery. Clin Chem. 2002;48(8):1160–1169.
   PubMed Web of Science ®Google Scholar
• Kim H, Kim K, Yu SJ, et al. Development of biomarkers for screening hepatocellular carcinoma using global data mining and multiple reaction monitoring. PLoS One. 2012;8(5):e63468.
   Google Scholar
• Schirle M, Bantscheff M, Kuster B. Mass spectrometry-based proteomics in preclinical drug discovery. Chem Biol. 2012;19(1):72–84.
   PubMed Web of Science ®Google Scholar
• Liu Y, Guo M. Chemical proteomic strategies for the discovery and development of anticancer drugs. Proteomics. 2014;14(4–5):399–411.
   PubMed Web of Science ®Google Scholar
• Sutton CW. The role of targeted chemical proteomics in pharmacology. Br J Pharmacol. 2012;166(2):457–475.
   PubMed Web of Science ®Google Scholar
• Yuan K, Lei Y, Huang C. Application of chemistry-based functional proteomics to screening for novel drug targets. Comb Chem High Throughput Screen. 2010;13(5):414–421.
   PubMed Web of Science ®Google Scholar
• Wang K, Yang T, Wu Q, et al. Chemistry-based functional proteomics for drug target deconvolution. Expert Rev Proteomics. 2012;9(3):293–310.
   PubMed Web of Science ®Google Scholar
• Rix U, Superti-Furga G. Target profiling of small molecules by chemical proteomics. Nat Chem Biol. 2009;5(9):616–624.
   PubMed Web of Science ®Google Scholar
• Bello E, Colella G, Scarlato V, et al. E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models. Cancer Res. 2011;71(4):1396–1405.
   PubMed Web of Science ®Google Scholar
• Colzani M, Noberini R, Romanenghi M, et al. Quantitative chemical proteomics identifies novel targets of the anti-cancer multi-kinase inhibitor E-3810. Mol Cell Proteom MCP. 2014;13(6):1495–1509.
   PubMed Web of Science ®Google Scholar
• Sartippour MR, Seeram NP, Heber D, et al. Rabdosia rubescens inhibits breast cancer growth and angiogenesis. Int J Oncol. 2005;26(1):121–127.
   PubMed Web of Science ®Google Scholar
• Dal Piaz F, Cotugno R, Lepore L, et al. Chemical proteomics reveals HSP70 1A as a target for the anticancer diterpene oridonin in Jurkat cells. J Proteomics. 2013;82:14–26.
   PubMed Web of Science ®Google Scholar
• Sawyers C. Targeted cancer therapy. Nature. 2004;432(7015):294–297.
   PubMed Web of Science ®Google Scholar
• Celis JE, Gromov P, Cabezón T, et al. Proteomic characterization of the interstitial fluid perfusing the breast tumor microenvironment A novel resource for biomarker and therapeutic target discovery. Mol Cell Proteomics. 2004;3(4):327–344.
   PubMed Web of Science ®Google Scholar
• Rauser S, Marquardt C, Balluff B, et al. Classification of HER2 receptor status in breast cancer tissues by MALDI imaging mass spectrometry. J Proteome Res. 2010;9(4):1854–1863.
   PubMed Web of Science ®Google Scholar
• Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. New Engl J Med. 2005;353(16):1673–1684.
   PubMed Web of Science ®Google Scholar
• Cohen AA, Geva-Zatorsky N, Eden E, et al. Dynamic proteomics of individual cancer cells in response to a drug. Science. 2008;322(5907):1511–1516.
   PubMed Web of Science ®Google Scholar
• Ortiz PA, Bruno ME, Moore T, et al. Proteomic analysis of propiconazole responses in mouse liver: comparison of genomic and proteomic profiles. J Proteome Res. 2010;9(3):1268–1278.
   PubMed Web of Science ®Google Scholar
• Klein O, Rohwer N, De Molina KF, et al. Application of two-dimensional gel-based mass spectrometry to functionally dissect resistance to targeted cancer therapy. Proteomics Clin Appl. 2013;7(11-12):813–824.
   Web of Science ®Google Scholar
• Chen R, Mias GI, Li-Pook-Than J, et al. Personal omics profiling reveals dynamic molecular and medical phenotypes. Cell. 2012;148(6):1293–1307.
   PubMed Web of Science ®Google Scholar
• Caudle KE, Klein TE, Hoffman JM, et al. Incorporation of pharmacogenomics into routine clinical practice: the clinical pharmacogenetics implementation consortium (CPIC) guideline development process. Curr Drug Metab. 2014;15(2):209–217.
   PubMed Web of Science ®Google Scholar
• McCarthy MI. Genomics, type 2 diabetes, and obesity. N Engl J Med. 2010;363(24):2339–2350.
   PubMed Web of Science ®Google Scholar
• Britton LM, Sova P, Belisle S, et al. A proteomic glimpse into the initial global epigenetic changes during HIV infection. Proteomics. 2014;14(19):2226–2230.
   PubMed Web of Science ®Google Scholar
• Marino G, Eckhard U, Overall CM. Protein termini and their modifications revealed by positional proteomics. ACS Chem Biol. 2015;10(8):1754–1764.
   PubMed Web of Science ®Google Scholar
• Rogers LD, Overall CM. Proteolytic post-translational modification of proteins: proteomic tools and methodology. Mol Cell Proteom MCP. 2013;12(12):3532–3542.
   PubMed Web of Science ®Google Scholar
• Eckhard U, Marino G, Butler GS, et al. Positional proteomics in the era of the human proteome project on the doorstep of precision medicine. Biochimie. 2016;122:110–118.
   PubMed Web of Science ®Google Scholar
• Nishi A, Milner DA Jr., Giovannucci EL, et al. Integration of molecular pathology, epidemiology and social science for global precision medicine. Expert Rev Mol Diagn. 2016;16(1):11–23.
   PubMed Web of Science ®Google Scholar
• Ogino S, Chan AT, Fuchs CS, et al. Molecular pathological epidemiology of colorectal neoplasia: an emerging transdisciplinary and interdisciplinary field. Gut. 2011;60(3):397–411.
   PubMed Web of Science ®Google Scholar
• Ogino S, Lochhead P, Chan AT, et al. Molecular pathological epidemiology of epigenetics: emerging integrative science to analyze environment, host, and disease. Modern Pathol. 2013;26(4):465–484.
   PubMed Web of Science ®Google Scholar
• Ogino S, Nosho K, Meyerhardt JA, et al. Cohort study of fatty acid synthase expression and patient survival in colon cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2008;26(35):5713–5720.
   PubMed Web of Science ®Google Scholar
• Ogino S, Campbell PT, Nishihara R, et al. Proceedings of the second international molecular pathological epidemiology (MPE) meeting. Cancer Causes Control. 2015;26(7):959–972.
   PubMed Web of Science ®Google Scholar
• Kikuchi T, Carbone DP. Proteomics analysis in lung cancer: challenges and opportunities. Respirology. 2007;12(1):22–28.
   PubMed Web of Science ®Google Scholar
• Pawa N, Wright JM, Arulampalam TH. Mass spectrometry based proteomic profiling for pancreatic cancer. JOP J Pancreas. 2010;11(5):423–426.
   PubMedGoogle Scholar